5 Lp(a) and PAD Toolkit: Emerging Diagnosis and Management Geoffrey Barnes, MD, MSc, FAHA, is a cardiologist and vascular medicine specialist at the University of Michigan Frankel Cardiovascular Center. Dr. Barnes is an NIH-funded health services researcher who is active in advancing the care of patients with thrombotic conditions, including peripheral artery disease. He is a leader with several national societies and currently serves as the fellowship director for the University of Michigan Vascular Medicine Fellowship program. Disclosures: Professional Services and Activities – Employment: University of Michigan Professional Services and Activities – Consultant: Acelis Connected Health, Bayer, Janssen Biotech, Inc., AstraZeneca, Pfizer, Anthos, BristolMyers Squibb, Sanofi, Abbott Vascular Financial Support – Grant/Contract: Boston Scientific Corporation Heather Harker Ryan, RN, PhD, CPN, FPCNA, is the clinical nurse educator and nurse scientist for the ambulatory division of the Cambridge Health Alliance in Cambridge, Massachusetts. Her program of research focuses on the identification and treatment of children and families affected by familial hypercholesterolemia. She currently holds leadership positions in a number of national organizations related to nursing leadership and cardiovascular care. Disclosures: Professional Services and Activities – Employment: Cambridge Health Alliance, Massachusetts General Hospital, University of Massachusetts Boston, Boston Children’s Hospital P. Barton Duell, MD, FAHA, MNLA, is an endocrinologist and lipid specialist at the Oregon Health & Science University where he is a professor of medicine in the Center for Preventive Cardiology, Knight Cardiovascular Institute and the Division of Endocrinology, Diabetes, and Clinical Nutrition. He is the director of the Lipoprotein Apheresis Unit and Sterol Analysis Laboratory at OHSU, as well as the co-editor-in-chief of the Journal of Clinical Lipidology. He serves/has served in leadership roles in various organizations including the AHA. He has been involved in numerous phase I-IV research studies related to lipid metabolism and ASCVD risk and has been evaluating and treating patients with elevated Lp(a) for more than 35 years. Disclosures: Professional Services and Activities – Employment: Oregon Health & Science University Professional Services and Activities – Consultant: Esperion Therapeutics Inc., Kaneka Pharma America LLC, Novo Nordisk, Regeneron Pharmaceuticals, Travere Therapeutics, Inc. Professional Services and Activities – Data and Safety Monitoring: Ionis Financial Support – Grant/Contract: Boston Scientific Corporation
RkJQdWJsaXNoZXIy MjI2NjI=